Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00455923
Status:
COMPLETED
Last Update Posted:
2018-02-05
First Post:
2007-04-03
Brief Title:
SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma GINAII
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
SERETIDE vs FLIXOTIDE in Mild Persistent Asthma GINAII
Status:
COMPLETED
Status Verified Date:
2018-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An 18 months randomised double-blind study with two parallel arms with start dose of inhaled SERETIDE 50100mcg BD or FLIXOTIDE 100mcg BD Phase I is 6 months where the patient will be up-titrated until well controlled is achieved After 6 months the treatment continues without changes during 9 months PhaseII The aim is to investigate and evaluate the assumption that the combination therapy with SERETIDE controls mild persistent asthma better than inhaled corticosteroidsFLIXOTIDE alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None